SCHEDULE: Third Rock Ventures Discloses 11.3% Stake in Maze Therapeutics

Third Rock Ventures entities have reported a combined beneficial ownership of 11.3% in Maze Therapeutics, Inc. common stock.

Summary

• Third Rock Ventures IV, L.P. and its general partners beneficially own 4,473,958 shares of Maze Therapeutics, Inc. common stock.
• This ownership by Third Rock Ventures IV entities represents 9.3% of the outstanding common stock.
• Third Rock Ventures V, L.P. and its general partners beneficially own 950,800 shares of Maze Therapeutics, Inc. common stock.
• This ownership by Third Rock Ventures V entities represents 2.0% of the outstanding common stock.
• The total beneficial ownership by Third Rock Ventures entities is 5,424,758 shares, representing a combined 11.3% of the class.
• The percentage of class was calculated based on 48,119,440 shares of common stock issued and outstanding as of November 3, 2025, as disclosed in the Issuer's 10-Q filed on November 6, 2025.
• All reported shares are held with shared voting and dispositive power by the respective Third Rock Ventures entities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a substantial stake by a venture capital firm like Third Rock Ventures suggests continued confidence in Maze Therapeutics' potential.

Positives

• A significant and continued ownership stake by a prominent venture capital firm like Third Rock Ventures can be interpreted as a positive signal of confidence in Maze Therapeutics' long-term potential and strategic direction.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that venture capital firms like Third Rock Ventures often take significant stakes in early-stage or growth-oriented biotechnology companies, indicating a long-term investment thesis based on potential drug development or platform technology success. This filing confirms Third Rock Ventures' continued substantial interest in Maze Therapeutics.

Stakeholder Impact

• Shareholders: The disclosure of a significant, continued stake by a major venture capital firm may instill confidence and potentially influence investor sentiment positively.
• Company Management: Indicates continued backing from a key early investor, potentially aligning interests for long-term growth.

Key Dates

Recommendation

A Schedule 13G filing primarily reports beneficial ownership and does not provide sufficient information on its own to warrant a 'buy' or 'sell' recommendation. However, the continued significant stake by a prominent venture capital firm like Third Rock Ventures suggests a long-term investment perspective, supporting a 'hold' recommendation for existing investors while awaiting further operational or financial updates.

Keywords

Maze Therapeutics, Third Rock Ventures, Beneficial Ownership, Schedule 13G, Common Stock, Venture Capital, Biotechnology, Investment